Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus‐Eluting Stents in Real‐World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry
Clinical Cardiology · 2024
DOI: 10.1002/clc.70060 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Ho Sung Jeon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Angiography, Coronary Artery Disease, Drug-Eluting Stents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by a grant from the Yonsei University Wonju College of Medicine..
Abstract (Originalsprache)
Background
The Orsiro and Genoss DES stents are biodegradable polymer drug‐eluting stents (DESs) with ultrathin struts.
Objective
To investigate the safety and efficacy of these two ultrathin DESs in real‐world practice.
Methods
From a single‐center prospective registry, we included 751 and 931 patients treated with the Genoss DES and Orsiro stents, respectively. After propensity score matching, we compared 483 patients in each group with respect to a device‐oriented composite outcome (DOCO), which comprised cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization up to 2 follow‐up years.
Results
After propensity score matching, there were no significant between‐group differences in clinical and angiographic characteristics. During the median follow‐up period of 730 days (interquartile range, 427–730 days), there was no significant between‐group difference in the DOCO rate (3.1% in the Genoss DES group vs. 2.9% in the Orsiro group, log‐rank p = 0.847).
Conclusions
This study demonstrated comparable safety and efficacy between the Orsiro and Genoss DES stents during a 2‐year follow‐up period in real‐world practice. However, this result should be confirmed in a large randomized controlled trial. Trial Registration ClinicalTrials.gov Identifier: NCT02038127.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.
Förderung
- This study was funded by a grant from the Yonsei University Wonju College of Medicine.
Zitieren
APA
Jeon, H. S., Youn, Y. J., Lee, J. H., Park, Y. J., Son, J. W., Lee, J. W., Ahn, M. S., Ahn, S. G., Kim, J. Y., Yoo, B. S., & Yoon, J. (2024). Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus‐Eluting Stents in Real‐World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry. Clinical Cardiology. https://doi.org/10.1002/clc.70060
Vancouver
Jeon HS, Youn YJ, Lee JH, Park YJ, Son JW, Lee JW, et al. Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus‐Eluting Stents in Real‐World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry. Clinical Cardiology. 2024. doi:10.1002/clc.70060
BibTeX
@article{Jeon2024,
author = {Jeon, Ho Sung and Youn, Young Jin and Lee, Jung-Hee and Park, Young Jun and Son, Jung-Woo and Lee, Jun-Won and Ahn, Min-Soo and Ahn, Sung Gyun and Kim, Jang-Young and Yoo, Byung-Su and Yoon, Junghan},
title = {Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus‐Eluting Stents in Real‐World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.70060}
}
EUVIMED